Lb Pharmaceuticals (LBRX) Common Equity (2024 - 2026)

Lb Pharmaceuticals has reported Common Equity for 3 years, with the latest figure at $378.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 481.22% year-over-year to $378.7 million; the trailing twelve-month figure through Mar 2026 stood at $378.7 million (up 481.22% YoY), and the FY2025 full-year result was $301.3 million, up 418.66% from the prior year.
• Common Equity for Q1 2026 stood at $378.7 million, up from $301.3 million in the prior quarter.
• The five-year high for Common Equity was $378.7 million in Q1 2026, with the low at -$99.3 million in Q1 2025.
• Average Common Equity over 3 years is $117.5 million, with a median of $104.9 million recorded in 2024.
• Year-over-year, Common Equity jumped 418.66% in 2025 and surged 481.22% in 2026.
• Tracing LBRX's Common Equity over 3 years: stood at -$94.6 million in 2024, then jumped by 418.66% to $301.3 million in 2025, then gained by 25.68% to $378.7 million in 2026.
• The last three Common Equity figures came in at $378.7 million (Q1 2026), $301.3 million (Q4 2025), and $310.2 million (Q3 2025), per Business Quant data.

Peer Comparison